Thyroid Disease and Pregnancy – American Thyroid Association

How long do pregnancy-related thyroid problems last? – Clinical Thyroidology® for the Public

ATA — Wed, 13 Aug 2025 12:41:01 +0000

From Clinical Thyroidology^® for the Public: Disorders of the thyroid, including autoimmune disorders, can develop during pregnancy. It is recognized that test results of thyroid function vary in pregnancy based on the pregnancy trimester. This study aims to analyze thyroid function changes in different trimesters of pregnancy and compare these changes with pregnancy outcomes. Read More…

We welcome your feedback and suggestions. Let us know what you want to see in this publication.

Feedback & Suggestions

The post How long do pregnancy-related thyroid problems last? – Clinical Thyroidology® for the Public appeared first on American Thyroid Association.

Clinical Thyroidology® for the Public – Highlighted Article

ATA — Fri, 11 Aug 2023 18:37:58 +0000

From Clinical Thyroidology^® for the Public: Rates of thyroid cancer has increased in recent years, especially in young woman. As such, people have been interested to know potential impact of thyroid cancer treatment on fertility. This study aimed to assess potential impact of thyroid cancer treatment on fertility and pregnancy rate in women in Israel. Read More…

We welcome your feedback and suggestions. Let us know what you want to see in this publication.

Feedback & Suggestions

The post Clinical Thyroidology^® for the Public – Highlighted Article appeared first on American Thyroid Association.

Thyroid Health – Management of Hypothyroidism During Pregnancy: When and how to treat?

ATA — Thu, 13 Aug 2020 20:07:46 +0000

Vibhavasu Sharma, MD, FACE
Albany Medical College, Albany, NY
August 13, 2020

Thyroid disease is commonly encountered during pregnancy. Women may already have the diagnosis prior to conception or may be first diagnosed after becoming pregnant. In the absence of thyroid disease, the gland is able to compensate for increased demand during pregnancy. However, gestation does present unique challenges to thyroid hormone management. Our current scientific understanding can provide some practical guidance to optimize care.

Maternal hypothyroidism is defined as a thyroid stimulating hormone (TSH) concentration above the trimester specific reference range. Use of population and trimester specific reference ranges is ideal, but is often not available. When not available, a TSH level above 4 mU/L may be used for diagnosis.

Women who already have a known diagnosis of hypothyroidism prior to pregnancy should have preconception counseling regarding disease management during pregnancy. A discussion of the goals of treatment and potential adverse maternal and fetal/child health outcomes is recommended.

Levothyroxine dose should be adjusted to target a TSH level between the lower limit of the reference range and 2.5 mU/L. The patient may be advised to increase the dose of levothyroxine by 20 to 30 % as soon as pregnancy is confirmed to avoid any inadvertent delay. One way to achieve this easily is by increasing the dose by two extra daily doses a week.

Continuation of or starting the use of desiccated thyroid or triiodothyronine(T3) preparations is not currently recommended during pregnancy. It is believed that thyroxine (T4) is essential for the developing fetal brain. The high ratio of T3 to T4 in these preparations may lead to a decreased transfer of maternal T4 to the fetal brain across the placenta, which is impermeable to T3.

Thyroid function testing should be done frequently, at least once every 4 weeks or with any dose changes to ensure the goals of therapy are being met. The frequency may be reduced after mid gestation. Levothyroxine should be adjusted based on the TSH values, with the recommended goal being a TSH in the lower half of a trimester-specific reference range, or simply a TSH below 2.5 mU/L when using a standard reference range.

For women not previously diagnosis with hypothyroidism or not taking levothyroxine, another issue of importance is subclinical hypothyroidism. For pregnancy, this is defined as an elevated TSH >4 mU/L, or above the pregnancy specific references range, in the presence of a normal serum T4 (thyroxine) concentration. This is where testing for the thyroid antibody levels may be particularly useful. Although there are limitations to the available data, it is recommended that women with subclinical hypothyroidism who have positive thyroid peroxidase (TPO) antibody levels be treated with levothyroxine. The potential benefit of this approach is a reduction in the rate of miscarriage (this risk has been shown to be higher in women who have this antibody). In the absence of TPO antibody, however, a higher TSH level of 10 mU/L may be utilized as guide to start treatment. Some endocrinologists may choose however, to initiate therapy at a TSH level below this number.

Two very important situations are worth noting. Women who take levothyroxine due to the previous treatment of Graves’ disease should have a TRAB (thyroid receptor binding antibody) level checked early in pregnancy and again around 18 to 22 weeks gestation if initially elevated. This is due to the increased risk of placental transfer and resulting fetal/neonatal hyperthyroidism/goiter. In patients with positive antibodies, obstetricians may need to follow the pregnancy closely with serial fetal ultrasounds and postnatal thyroid function tests.

It is also important to remember to readjust the levothyroxine dose post-partum. Levothyroxine can typically be returned to the pre-pregnancy dose. The patient should have thyroid function testing about 6 weeks post-partum and the dose may be now adjusted to a goal of keeping the TSH in the normal range. Women who did not have hypothyroidism before pregnancy and do not have immediate plans for future fertility may consider discontinuation of levothyroxine.

A careful evidence-based approach to the management of hypothyroidism with preconception counseling, close laboratory monitoring and keeping the goals of treatment with levothyroxine in mind can help manage the condition well and reduce the risk of adverse outcomes.

For further reference:

2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.

Thyroid Disease in Pregnancy Brochure | by the American Thyroid Association

Disclaimer:
The ideas and opinions expressed in the ATA Thyroid Health Blogs do not necessarily reflect those of the ATA. None of the information posted on link to blog page is intended as medical, legal, or business advice, or advice about reimbursement for health care services. The mention of any product, service, company, therapy or physician practice on link to blog page does not constitute an endorsement of any kind by ATA. ATA assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in, posted on, or linked to this site, or any errors or omissions.

The post Thyroid Health – Management of Hypothyroidism During Pregnancy: When and how to treat? appeared first on American Thyroid Association.

Disorders of Thyroid Function Presentations at American Thyroid Association: 88th Annual Meeting

ATA — Mon, 01 Oct 2018 22:38:38 +0000

October 2, 2018—The American Thyroid Association (ATA) will hold its 88^th Annual Meeting on October 3‒7, 2018, at the Marriott Marquis in Washington, DC. In addition to the major speeches and awards, a variety of smaller presentations will be accessible to attendees in the form of posters and oral abstracts. One group of these concerns disorders of thyroid function.

1. Dr. Maia Banige will give a presentation titled “Prediction of fetal and neonatal dysthyroidism,” showing how imperfect development and function of the thyroid in fetuses (FD) and newborns (ND) can be predicted from perinatal variables. Dr. Banige is from the Department of Pediatrics-Neonatology and Pediatric Emergency of the French-British Hospital Institute, Levallois-Perret, Ile-de-France.She and her colleagues conducted a retrospective, multicenter study using data from the medical records of all patients monitored for pregnancy from 2007 to 2014 in 10 obstetric centers of the Assistance Publique des Hôpitaux de Paris. Women with Graves’ disease who were positive for thyrotropin receptor antibodies (TRAb) at least once during pregnancy were included. Among 280,000 births, 2,288 medical records of women with thyroid dysfunction were selected and screened, and 417 women with Graves’ disease who were positive for TRAb during pregnancy (0.15%) were finally included in the study.
  Analysis revealed that the TRAb level in the mother and child was the strongest independent predictor of thyroid dysfunction. The risk of FD and ND increases with maternal hormonal imbalance and is also greater in the patients receiving antithyroid drugs (ATDs) during pregnancy. In pregnant women with TRAb levels ≥2.5 IU/L, fetal ultrasound monitoring is essential until delivery. All newborns with TRAb levels ≥6.8 IU/L should be examined by a pediatrician with special attention for thyroid dysfunction.

1. A presentation titled “Pre-conception thyroid stimulating hormone level and risk of preterm birth in over 4.3 million rural Chinese women aged 20-49 years: a population-based cohort study” will be given by Dr. Ying Yang of the National Research Institute for Health and Family Planning and the National Human Genetic Resources Center. Dr. Ying and his colleagues studied the association between the pre-conception thyroid stimulating hormone (TSH) levels of women planning for pregnancy and the risk of preterm births (PTB).Researchers conducted a historical cohort study of 4,320,584 rural reproductive-age women who had participated in free National Free Pre-pregnancy Checkups (NFPC) in 2013-2016 in China. Data on preconception TSH, history of pregnancy and diseases, and other variables were obtained from the physical examination record in NFPC. Successful conception and pregnancy outcomes were documented during the follow-up period, June 2013 to December 2017. PTB is defined as any birth within 28 to 37 weeks of gestational age. Participants who failed to become pregnant within 6 months, suffered from fetal death or stillbirth, or had multiple gestations during the period of study were excluded from the analysis. The data documented 283,854 PTB events (6.57%).
  The study identified a V-shaped relationship between maternal pre-conception TSH levels and PTB risk. Either decreasing or increasing pre-conception TSH levels can significantly increase the risk of preterm birth.

1. Dr. George Kahaly of the Department of Medicine at Johannes Gutenberg University Medical Center in Mainz, Germany, and colleagues have undertaken a three-phase clinical trial of the drug teprotumumab. Results from the first phase—a 24-week randomized, double-masked, placebo-controlled treatment trial of the drug, which is an insulin-like growth-factor-1 receptor inhibitory antibody—were reported in the New England Journal of Medicine (NEJM 2017; 376:1748). Compared with a placebo (69% versus 20%), teprotumumab reduced protopsis (protrusion of the eyeballs) significantly beginning at week 6 and continuing over the 24 weeks of the trial. This second-phase report is an assessment of clinical status at weeks 28 and 72.At week 28 (4 weeks after the treatment period), proptosis response was 73.8% in the teprotumumab group versus 13.3% in controls. At week 72 (48 weeks after treatment), 53% of week 24 teprotumumab proptosis responders maintained ≧ 2 mm improvement relative to baseline. Compared to baseline and placebo, clinical activity also decreased at week 28 and was relatively unchanged in the teprotumumab group at week 72. These results indicate no acute rebound of disease following the 24-week treatment.
  Dr. Kahaly’s group conclude that teprotumumab may represent a disease-modifying therapy in TAO by reducing proptosis and clinical activity, with sustained effects seen in most patients 48 weeks after treatment. In phase 3 of the trial, the research group will investigate whether patients would benefit from longer treatment or retreatment with teprotumumab.

Dr. Mats Holmberg of Institute of Medicine, Sahlgrenska Academy, and the Karolinska University Hospital, ANOVA, both in Stockholm, Sweden, will present a study titled “Structural brain changes in Graves’ hyperthyroidism may be of autoimmune origin.” During the hyperthyroid state of Graves’ disease (GD), the volumes of medial temporal lobe (MTL) structures, e.g., the hippocampi, are reduced. This has been attributed to high thyroid hormone levels, but Dr. Holmberg and his colleagues hypothesized that the structural changes and mental symptoms may be due to autoimmunity per se. The aim of their study was to determine the relationship between nonthyroid autoimmunity and MTL volumes during hyperthyroidism in GD.Dr. Holmberg’s project is a longitudinal, observational, prospective case-controlled study in which 65 premenopausal women were evaluated within 2 weeks after a diagnosis of GD and again after 15 months of antithyroid treatment. Thyroid-stimulating hormone receptor antibodies, thyroid-stimulating immunoglobulins, and several additional antibodies were measured in the hyperthyroid state. MTL structures were scanned to determine hippocampal and amygdala volumes. This presentation reports preliminary data on the nonthyroid antibodies at baseline. Data on the thyroid antibodies will be reported separately.
The data so far support the hypothesis that autoimmunity that is not directly connected to the thyroid may be involved in the impairment of brain function in GD, introducing a new concept that needs further study.

###

The American Thyroid Association (ATA) is the leading worldwide organization dedicated to the advancement, understanding, prevention, diagnosis, and treatment of thyroid disorders and thyroid cancer. ATA is an international membership medical society with over 1,700 members from 43 countries around the world. Celebrating its 95^th anniversary, the ATA continues to deliver its mission of being devoted to thyroid biology and to the prevention and treatment of thyroid disease through excellence in research, clinical care, education, and public health. These efforts are carried out via several key endeavors:

The publication of the highly regarded professional journals Thyroid, Clinical Thyroidology, and VideoEndocrinology
Annual scientific meetings
Biennial clinical and research symposia
Research grant programs for young investigators
Support of online professional, public, and patient educational programs
Development of guidelines for clinical management of thyroid disease and thyroid cancer

The ATA promotes thyroid awareness and information online through Clinical Thyroidology for the Public and extensive, authoritative explanations of thyroid disease and thyroid cancer in both English and Spanish. The ATA website serves as the clinical resource for patients and the public who look for reliable information on the Internet. Every fifth year, the American Thyroid Association joins with the Latin American Thyroid Society, the European Thyroid Association, and the Asia and Oceania Thyroid Association to cosponsor the International Thyroid Congress (ITC).

The post Disorders of Thyroid Function Presentations at American Thyroid Association: 88^th Annual Meeting appeared first on American Thyroid Association.

Research Grant to Study the Action of T-Regulatory Cells in Thyroid-Antibody-Positive Pregnant Women Awarded to Stephanie Behringer-Massera, MD, by the American Thyroid Association

ATA — Thu, 16 Aug 2018 21:26:37 +0000

Stephanie Behringer-Massera, MD
Icahn School of Medicine at Mount Sinai
New York, NY
Bio

The American Thyroid Association has awarded a 2018 Research Grant to Stephanie Behringer-Massera, MD, Clinical Fellow at the Icahn School of Medicine at Mount Sinai. Dr. Behringer-Massera’s project is titled “T regulatory cells in thyroid-antibody-positive pregnant women.”

A fetus, which shares half its genetic material with the father, is considered a foreign body in the mother’s womb. The only way that it can implant in the uterus without being rejected is if the mother’s immune system is suppressed, which happens through T-regulatory-cell action. The more T regulatory cells (Tregs) are released, the more the immune system is suppressed and the more likely the pregnancy can successfully be brought to term. In women with autoimmune thyroid disease, this process is disrupted. These women are found to have an abnormal Treg response to pregnancy and have Treg levels as low as women who are not pregnant. They are more likely to have miscarriages in the first trimester.

Through this project, Dr. Behringer-Massera hopes to understand the underlying pathology in this immune response to the fetus, enabling the development of targeted therapies to prevent these miscarriages. She plans to measure the proportion of Tregs in pregnant women during each trimester and in those who are 6-weeks postpartum, comparing the proportions in thyroid-antibody-positive versus thyroid-antibody-negative women, as well as in a control group of normal nonpregnant women. Her laboratory will also examine the functional status of Treg cells in both normal and thyroid-antibody positive women during pregnancy to determine their effectiveness at immune control. They will also analyze the Treg cells isolated from the control group and from the antibody-positive women to evaluate clonal expansion during and after pregnancy.

Dr. Behringer-Massera’s previous studies of patients with increased thyroid autoantibodies during the first trimester of pregnancy demonstrated the increased rate of miscarriage and led to her proposed further studies.

Dr. Behringer-Massera completed her medical studies at the University of Heidelberg in Germany in December 2009. She continued her medical training as a resident in Internal Medicine at the St. Josef Hospital in Heidelberg. In 2011 she was accepted for a residency in Internal Medicine at Montefiore Medical Center, Bronx, New York. She successfully completed her Internal Medicine training in 2014 and was awarded a research fellowship in the Empire Clinical Research Investigator Program (ECRIP) at the Albert Einstein College of Medicine, where she joined a multi-center clinical trial on glycemia-reduction approaches in diabetes (GRADE) funded by the NIH. During this time she also conducted a qualitative study on barriers to enrollment into research studies. In 2016 she started training as a Clinical Fellow in Endocrinology at the Mount Sinai Hospital in New York. When she completes her fellowship in June 2018, she will begin a position as Assistant Professor at the Icahn School of Medicine at Mount Sinai with clinical duties at Mount Sinai Beth Israel Medical Center.

Dr. Antonio Di Cristofano, Chair, ATA Research Committee, says, “The ATA research grant program represents a unique and invaluable mechanism to foster the development of a new generation of basic, translational, and clinical researchers. Through this program, we allow these outstanding young scientists to test innovative hypotheses and generate preliminary data that will give them a significant competitive advantage when applying for traditional NIH-type funding.

This year we received 63 applications from 18 countries, spanning the whole spectrum of thyroid-related research. While, through a rigorous process, we have selected the most promising projects for funding, at the same time we regret we had to leave behind a number of excellent proposals. We are extremely thankful for the support we receive from members and organizations, including thyroid cancer survivors, which makes this outstanding program possible and allows the ATA to nurture the next generation of leaders in thyroidology.”

The American Thyroid Association (ATA) has awarded 99 thyroid research grants totaling over $2.8 million since the inception of the Research Fund. In addition, the ATA rigorously manages the selection of research projects and the distribution of over $1.8 million generously donated to the ATA specifically for research grants from: ThyCa, the Thyroid Cancer Survivors’ Association, Inc.; Bite Me Cancer; and the Thyroid Head and Neck Cancer Foundation.

The Thyroid Cancer Survivors’ Association, Inc. (ThyCa), has provided funding since 2003 in support of 72.5 special research grants totaling $2,084,375 focused on thyroid cancer and medullary thyroid cancer. In 2018 ThyCa is supporting half of a new medullary thyroid cancer grant with Bite Me Cancer, two new thyroid cancer research grants, and four renewing grants. ThyCa is a member of the ATA Alliance for Patient Education. Find out more at www.thyca.org.

Bite Me Cancer (BMC) is our newest grant funder, supporting 8.5 thyroid cancer grants since 2014 for a total of $201,250. BMC will be supporting a half of a new medullary thyroid cancer grant in 2018 with ThyCa and one renewing thyroid cancer grant. BMC is a member of the ATA Alliance for Patient Education. Find out more at www.bitemecancer.org.

###

The American Thyroid Association (ATA) is the leading worldwide organization dedicated to the advancement, understanding, prevention, diagnosis, and treatment of thyroid disorders and thyroid cancer. ATA is an international, individual membership organization for over 1,700 clinicians and researchers from 43 countries around the world, representing a broad diversity of medical disciplines. It also serves the public, patients, and their families through education and awareness efforts.

Celebrating its 95th anniversary, ATA delivers its mission through several key endeavors: the publication of highly regarded monthly journals, Thyroid®, Clinical Thyroidology®, VideoEndocrinology, and Clinical Thyroidology for the Public; annual scientific meetings; biennial clinical and research symposia; research grant programs for young investigators; support of online professional, public, and patient educational programs; and the development of guidelines for clinical management of thyroid disease.

Find out more about ATA at www.thyroid.org.

The post Research Grant to Study the Action of T-Regulatory Cells in Thyroid-Antibody-Positive Pregnant Women Awarded to Stephanie Behringer-Massera, MD, by the American Thyroid Association appeared first on American Thyroid Association.

Clinical Thyroidology® for the Public – Highlighted Article

ATA — Fri, 22 Dec 2017 17:34:28 +0000

From Clinical Thyroidology^® for the Public: Prematurity is one of the most important causes of death in newborns and babies. Research has shown that both hyperthyroidism and hypothyroidism are associated with poor outcomes for the mother and the developing newborn, including premature delivery. Read More….

We welcome your feedback and suggestions. Let us know what you want to see in this publication.

Feedback & Suggestions

The post Clinical Thyroidology^® for the Public – Highlighted Article appeared first on American Thyroid Association.

Clinical Thyroidology for the Public – Highlighted Article

ATA — Mon, 21 Aug 2017 00:13:42 +0000

From Clinical Thyroidology for the Public: While it is clear that overt hypothyroidism in the mother during pregnancy can affect the baby’s brain development or cause other problems with the pregnancy, it is not clear if subclinical hypothyroidism would have similar adverse effects. Read More….

We welcome your feedback and suggestions. Let us know what you want to see in this publication.

Feedback & Suggestions

The post Clinical Thyroidology for the Public – Highlighted Article appeared first on American Thyroid Association.

American Thyroid Association Guidelines for Diagnosis and Management of Thyroid Disease During Pregnancy Published in Thyroid Journal

ATA — Sun, 15 Jan 2017 15:39:59 +0000

New evidence-based recommendations from the American Thyroid Association (ATA) provide guidance to clinicians in diagnosing and managing thyroid disease during pregnancy and the postpartum period. Pregnancy has a profound effect on thyroid gland function, and thyroid disease is common in pregnancy. The 97 recommendations presented in the new Guidelines help define current best practices for thyroid function testing, iodine nutrition, pregnancy complications, and treatment of thyroid disease during pregnancy and lactation. The American Thyroid Association (ATA) guidelines are available free on the website of Thyroid, the official peer-reviewed journal of the ATA, published by Mary Ann Liebert, Inc., publishers.

The “2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum” were coauthored by an international task force of expert clinicians and researchers in the field of thyroidology. Led by Co-chairs Erik Alexander MD, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA and Elizabeth Pearce, MD, MSc, Boston University School of Medicine, the task force provides a solid foundation of knowledge on the assessment and treatment of thyroid disease in women during pregnancy, preconception, and the postpartum period. The Guidelines include recommendations related to the diagnosis and management of hypothyroidism, thyrotoxicosis, thyroid nodules, and thyroid cancer, as well as thyroid considerations in infertile women, fetal and neonatal considerations, and directions for future research.

“These guidelines provide a superb overview on the pathophysiology and the clinical management of thyroid disorders during and after pregnancy. In addition, they also define areas where additional research is needed; this will allow keeping the document living with further updates in the coming years,” says Peter A. Kopp, MD, Editor-in-Chief of Thyroid and Professor of Medicine, Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago.

“Produced by an international panel of recognized experts, these updated guidelines add to the library of similar documents on thyroid disease that serve as the gold standard for diagnosis and management of thyroid disorders and identify critical areas where more research and knowledge is needed,” says, John C. Morris, III, MD, President of the ATA, Mayo Clinic, Rochester, MN.

“With an estimated 300,000 pregnancies impacted by thyroid disease in the United States annually, these guidelines coalesce the best available evidence into clear clinical recommendations, and will improve the health of many, many mothers and newborns alike,” say Dr. Alexander and Dr. Pearce.

About the Journal
Thyroid, the official journal of the American Thyroid Association, is an authoritative peer-reviewed journal published monthly online with open access options and in print. The Journal publishes original articles and timely reviews that reflect the rapidly advancing changes in our understanding of thyroid physiology and pathology, from the molecular biology of the cell to clinical management of thyroid disorders. Complete tables of content and a sample issue may be viewed on the Thyroid website. The complete Thyroid Journal Program includes the highly valued abstract and commentary publication Clinical Thyroidology, led by Editor-in-Chief Jerome M. Hershman, MD and published monthly, and the groundbreaking videojournal companion VideoEndocrinology, led by Editor Gerard Doherty, MD and published quarterly. Complete tables of content and sample issues may be viewed on the Thyroid website.

About the Society
The American Thyroid Association (ATA) is the leading worldwide organization dedicated to the advancement, understanding, prevention, diagnosis, and treatment of thyroid disorders and thyroid cancer. ATA is an international multi-discipline medical society with over 1,700 endocrinologists, surgeons, oncologists from 43 countries around the world. Celebrating its 94^th anniversary, the ATA delivers its mission—of being devoted to thyroid biology and to the treatment of thyroid disease through excellence in research, clinical care, education, and public health—through several key endeavors: the publication of highly regarded professional journals, Thyroid, Clinical Thyroidology, and VideoEndocrinology; annual scientific meetings; biennial clinical and research symposia; research grant programs for young investigators, support of online professional, public and patient educational programs; and the development of guidelines for clinical management of thyroid disease and thyroid cancer. The ATA promotes thyroid awareness and information through its online Clinical Thyroidology for the Public (distributed free of charge to over 11,000 patients and public subscribers) and extensive, authoritative explanations of thyroid disease and thyroid cancer in both English and Spanish. The ATA website serves as the clinical resource for patients and the public who look for reliable information on the Internet.

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Diabetes Technology & Therapeutics, Journal of Women’s Health, and Metabolic Syndrome and Related Disorders. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s more than 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

The post American Thyroid Association Guidelines for Diagnosis and Management of Thyroid Disease During Pregnancy Published in Thyroid Journal appeared first on American Thyroid Association.

More news from the 86th Annual Meeting of the ATA

ATA — Tue, 04 Oct 2016 21:10:57 +0000

ATA 2016 Meeting News Coverage
From Healio/Endocrine Today

Latest clinical, basic thyroid research highlighted at ATA annual meeting – September 21, 2016
Healio/Endocrine Today

Pregnancy loss, preterm delivery reduced with levothyroxine therapy – September 22, 2016
Healio/Endocrine Today

Hypocalcemia management strategies differ among physicians after thyroidectomy – September 22, 2016
Healio/Endocrine Today

Thyroid cancer overdiagnosis raises questions about overtreatment – September 22, 2016
Healio/Endocrine Today

Recommendations needed for TPOAb cut-off levels during pregnancy – September 23, 2016
Healio/Endocrine Today

Patients with Hashimoto’s thyroiditis require similar T ₄ levels regardless of body weight – September 23, 2016
Healio/Endocrine Today

The post More news from the 86th Annual Meeting of the ATA appeared first on American Thyroid Association.

American Thyroid Association in the News

ATA — Wed, 28 Sep 2016 22:03:48 +0000

Conference News
From Medscape Diabetes & Endocrinology
Coverage from the American Thyroid Association (ATA) 86th Annual Meeting

Lenvatinib: ‘Real-World’ Therapy for Differentiated Thyroid Cancer – September 23, 2016
Medscape
Nancy A Melville

Congenital Hypothyroidism Diagnosis Often Delayed – September 26, 2016
Medscape
Nancy A Melville

Subclinical Hypothyroidism in Pregnancy: Link to Premature Delivery
Medscape
Nancy A Melville

Long-term Results Support Low-Dose Radioiodine Efficacy for DTC – September 28, 2016
Medscape
Nancy A Melville

TPO-Antibody Positivity Often Falls Below Assay Cutoffs in Pregnancy – September 29, 2016
Medscape
Nancy A Melville

Meeting Highlights from American Thyroid Association 86th Annual Meeting
From EndocrineWeb
Presentation summaries provided to share emerging research and clinical advances in all aspects of thyroid patient care.

Circadian Rhythm Affects Outcome of FNA, May Impact Tumor Growth
Endocrine Web
Kathleen Doheny

Hyperthyroid Disease Linked to Higher Breast Cancer Risk
Endocrine Web
Kathleen Doheny

Managing Thyroid Nodules: Are Guidelines Being Met?
Endocrine Web
Kathleen Doheny

New Insights Regarding Thyroid-Obesity-Cancer Link
Endocrine Web
Kathleen Doheny

Precision Medicine: Evolving Rapidly
Endocrine Web
Kathleen Doheny

RAI: Beyond Evidence-Based Medicine to Manage Thyroid Cancer
Endocrine Web
Kathleen Doheny

Restraint Needed in Treating Thyroid Microcarcinomas
Endocrine Web
Kathleen Doheny

The post American Thyroid Association in the News appeared first on American Thyroid Association.

Thyroid Disease and Pregnancy – American Thyroid Association

How long do pregnancy-related thyroid problems last? – Clinical Thyroidology® for the Public

Clinical Thyroidology® for the Public – Highlighted Article

Thyroid Health – Management of Hypothyroidism During Pregnancy: When and how to treat?

Vibhavasu Sharma, MD, FACE Albany Medical College, Albany, NY August 13, 2020

For further reference:

Disorders of Thyroid Function Presentations at American Thyroid Association: 88th Annual Meeting

Research Grant to Study the Action of T-Regulatory Cells in Thyroid-Antibody-Positive Pregnant Women Awarded to Stephanie Behringer-Massera, MD, by the American Thyroid Association

Clinical Thyroidology® for the Public – Highlighted Article

Clinical Thyroidology for the Public – Highlighted Article

American Thyroid Association Guidelines for Diagnosis and Management of Thyroid Disease During Pregnancy Published in Thyroid Journal

More news from the 86th Annual Meeting of the ATA

ATA 2016 Meeting News Coverage From Healio/Endocrine Today

American Thyroid Association in the News

Conference News From Medscape Diabetes & Endocrinology Coverage from the American Thyroid Association (ATA) 86th Annual Meeting

Meeting Highlights from American Thyroid Association 86th Annual Meeting From EndocrineWeb Presentation summaries provided to share emerging research and clinical advances in all aspects of thyroid patient care.

Vibhavasu Sharma, MD, FACE
Albany Medical College, Albany, NY
August 13, 2020

ATA 2016 Meeting News Coverage
From Healio/Endocrine Today

Conference News
From Medscape Diabetes & Endocrinology
Coverage from the American Thyroid Association (ATA) 86th Annual Meeting

Meeting Highlights from American Thyroid Association 86th Annual Meeting
From EndocrineWeb
Presentation summaries provided to share emerging research and clinical advances in all aspects of thyroid patient care.